Hospital Universitario Reina Sofía
Córdoba, 14004, Spain
NCT Number: NCT04357860
Early administration of sarilumab in hospitalized patients infected with COVID-19 who have pulmonary infiltrates and are at high risk of unfavorable evolution could decrease/prevent progression to acute respiratory distress syndrome (ARDS) requiring high flow nasal oxygenation (HFNO) or either invasive or non-invasive mechanical ventilation.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Córdoba, 14004, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Best available treatment up to 14 days plus Sarilumab 200 mg
Best available treatment up to 14 days plus Sarilumab 400 mg
Best available treatment up to 14 days
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Proportion of patients requiring or time (in days) until required:
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Crude mortality at 28 days
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Time to clinical improvement: defined as the mean change or time in days from randomization to any of the following criteria: (i) improvement of two points on the ordinal scale of 7 points of severity or, (ii) hospital discharge with lifetime. The criteria reached before are used. The 7 point gravity scale includes the following categories:
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Time (in days) until improvement in oxygenation for at least 48 hours:
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Proportion of patients requiring invasive mechanical ventilation in the trial
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Proportion of patients having negative COVID-19 CRP at each visit of the trial
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Mean of serum cytokine levels: the panel of cytokines to quantify; IL1-��, IL1-β, IL6, IL8, IL10, IL12, IL18, IL38, INFɣ, TNF��, CCL2, CCL3, CCL4, MIF and PAI-1
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Incidence of adverse events related to medication and its administration
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Incidence in the appearance of serious bacterial, fungal or opportunistic infections in the subjects
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Incidence of perforation of the gastrointestinal tract in subjects
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Leukocyte and neutrophil count mean
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Mean hemoglobin levels
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Platelet count mean
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Average levels of creatinemia
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
Average bilirubin levels
Time frame: At day 28 or when the subject is discharged (whichever occurs first)
ALT and AST average levels
Maimónides Biomedical Research Institute of Córdoba
Other
Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome
Acronym: SARICOR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04444609
ARDS, Human, COVID-19
London, United Kingdom
View Trial DetailsNCT04359693
SARS-CoV 2
Lille, France
View Trial DetailsNCT04797091
Corona Virus Infection, Coronaviridae Infections
Cologne, Germany
View Trial DetailsNCT04392388
SARS-CoV 2
Paris, France
View Trial Details